Literature DB >> 14644278

Outcomes of active operation during intensive followup for second primary malignancy after esophagectomy for thoracic squamous cell esophageal carcinoma.

Satoru Motoyama1, Reijiro Saito, Michihiko Kitamura, Jun-ichi Ogawa.   

Abstract

BACKGROUND: Recent advances in the treatment of thoracic esophageal cancer have afforded it a better prognosis. As a consequence, increasing attention is being paid to the outcomes with postoperative monitoring for second primary malignancies after esophagectomy, but no recent study has focused on the longterm followup and outcomes in these patients. STUDY
DESIGN: In 1989, we began intensive prospective screening and surveillance designed to detect cancers of the head and neck, lung, stomach, residual esophagus, and colon/rectum after esophagectomy. Between 1989 and 2001, 365 patients underwent esophagectomy for thoracic squamous cell esophageal carcinoma in our department. Of those, 200 were followed up as part of this program. Excluded were patients in whom esophageal cancer recurred, patients with other prior or simultaneous malignancies, and patients who died within a year of operation. Clinicopathologic profiles and treatment outcomes were determined for 33 patients who developed a second primary malignancy after esophagectomy.
RESULTS: The interval between the primary esophageal cancer and the secondary carcinoma was 49 +/- 40 months (median, 48 months). The second primary malignancies were located in the stomach (30%), head and neck (24%), lung (24%), colon/rectum (9%), liver (6%), pancreas (3%), and blood (6%). Twenty-one patients (64%) were classified as stage 0, I, or II; 10 (30%) were stage III or IV. Overall, the 2-year, 3-year, and 5-year survival rates following diagnosis of a second primary malignancy were 58.0%, 58.0%, and 48.6%, respectively. Of the 19 patients (58%) in whom second primary malignancies were detected before symptoms developed, the 5-year survival rate was 70.7%, which was significantly greater than that among patients whose secondary malignancies were discovered after symptoms developed (17.1%).
CONCLUSIONS: Good outcomes in the treatment of second primary malignancies after esophagectomy for thoracic squamous cell esophageal carcinoma can be obtained with longterm, intensive followup and active surgical intervention for detected malignancies.

Entities:  

Mesh:

Year:  2003        PMID: 14644278     DOI: 10.1016/j.jamcollsurg.2003.07.014

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  9 in total

1.  Metachronous adenocarcinoma in a gastric tube after radical surgery for oesophageal cancer.

Authors:  Justyna Izabela Zygoń; Jarosław Skokowski; Jacek Zieliński; Kamil Drucis; Katarzyna Golabek-Dropiewska
Journal:  BMJ Case Rep       Date:  2010-03-11

2.  Endoscopic submucosal dissection for early neoplastic lesions in the surgically altered stomach: a systematic review and meta-analysis.

Authors:  Mohamed Barakat; Mohamed Seif; Mohamed M Abdelfatah; Andrew Ofosu; David L Carr-Locke; Mohamed O Othman
Journal:  Surg Endosc       Date:  2019-04-08       Impact factor: 4.584

3.  Estimating the need for neck lymphadenectomy in submucosal esophageal cancer using superparamagnetic iron oxide-enhanced magnetic resonance imaging: clinical validation study.

Authors:  Satoru Motoyama; Koichi Ishiyama; Kiyotomi Maruyama; Komei Narita; Yoshihiro Minamiya; Jun-Ichi Ogawa
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

4.  Outcome and treatment strategy for mid- and lower-thoracic esophageal cancer recurring locally in the lymph nodes of the neck.

Authors:  Satoru Motoyama; Michihiko Kitamura; Reijiro Saito; Kiyotomi Maruyama; Manabu Okuyama; Jun-ichi Ogawa
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

5.  Mesojejunal lymph node metastasis in esophageal cancer following total gastrectomy.

Authors:  Takashi Ono; Satoru Motoyama; Reijiro Saito; Manabu Okuyama; Hiroshi Imano; Jun-ichi Ogawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-11

6.  Superior mediastinal and neck lymphatic mapping in mid- and lower-thoracic esophageal cancer as defined by ferumoxides-enhanced magnetic resonance imaging.

Authors:  Hiroshi Imano; Satoru Motoyama; Reijiro Saito; Yoshihiro Minamiya; Yoshihisa Katayose; Manabu Okuyama; Masakatsu Nakamura; Koichi Ishiyama; Ryuji Sashi; Jun-ichi Ogawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-10

7.  Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysis.

Authors:  Laurelle van Tilburg; Steffi E M van de Ven; Manon C W Spaander; Laurens A van Kleef; Robin Cornelissen; Marco J Bruno; Arjun D Koch
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

8.  Secondary primary malignancy risk among patients with esophageal cancer in Taiwan: a nationwide population-based study.

Authors:  San-Chi Chen; Chung-Jen Teng; Yu-Wen Hu; Chiu-Mei Yeh; Man-Hsin Hung; Li-Yu Hu; Fan-Chen Ku; Cheng-Hwai Tzeng; Tzeon-Jye Chiou; Tzeng-Ji Chen; Chia-Jen Liu
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

9.  Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: A systematic review and meta-analysis.

Authors:  Sem van de Ven; O Bugter; J A Hardillo; M J Bruno; R J Baatenburg de Jong; A D Koch
Journal:  United European Gastroenterol J       Date:  2019-06-05       Impact factor: 4.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.